CONTENTS:
- Removing arbitrary limitations on buprenorphine for opioid use disorder [Editorial]. Gastala N., Hudak B., Pho M.T., Pollack H.A., Wilcox K., p. 1913-1915.
- Sludge, dark patterns and dark nudges: A taxonomy of online gambling platforms' deceptive design features [Addiction opinion and debate]. Newall P., p. 1916-1923.
- Gambling website design as a factor in North American betting expansion. Clark L., Weston P.W., p. 1924-1926.
- Reducing gambling harm requires a balanced focus on commercial factors, individual differences and their interaction. Field M., Gaskell M., p. 1927-1928.
- Research priorities in deceptive online gambling platform design research: We need to understand behavioral usage patterns in order to inform safer platform design. Newall P., p. 1929-1930.
- Craving self-reports as outcome measures in drug addiction trials: A systematic review of ClinicalTrials.gov. Toulami M., Ghasemi K., Rafei P., Sangchooli A., Nafissi N., Khojasteh Zonoozi A., et al., p. 1931-1950.
- The impacts of policies controlling the spatial availability of take-away alcohol on consumption and harms: A systematic narrative review. Shakory S., Smith B.T., Jansen R., Reel B., Hobin E., p. 1951-1969.
- The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options. Harding R.E., Barton T., Niepceron M., Harris E., Bennett E., Gent E., et al., p. 1970-1979.
- Commentary on Harding et al.: Responding to ketamine use disorder - Integrating practice, research, and whole-system approaches to harm reduction. Ralphs R., Day J., Dewhurst J., p. 1980-1981.
- Effects of legal access versus illegal market cannabis on use and mental health: A randomized controlled trial. Baltes-Flueckiger L., Steinauer R., Meyer M., Guessoum A., Herrmann O., Mosandl C.F., et al., p. 1982-1992.
- Commentary on Baltes-Flueckiger et al.: Rethinking expectations and evidence in cannabis policy. Sznitman S.R., Auer R., Broers B., p. 1993-1994.
- Synthetic cannabinoids in e-cigarettes seized from English schools. Cozier G.E., Gardner M., Craft S., Skumlien M., Spicer J., Andrews R., et al., p. 1995-2004.
- Healthcare provider stigma toward patients with substance use disorders. Parish C.L., Feaster D.J., Pollack H.A., Horigian V.E., Wang X., Jacobs P., et al., p. 2005-2019.
- Social cognition and decision-making in people with methamphetamine use disorder. Mahlberg J., Hanegraaf L., Zimmermann J., Cole D.M., Quednow B.B., Arunogiri S., et al., p. 2020-2031.
- An age-period-cohort-interaction analysis of meth/amphetamine-related deaths in Australia, 2001-2020. Stronach O., Dietze P., Livingston M., Roxburgh A., p. 2032-2043.
- Identifying key risk factors for intentional self-harm, including suicide, among a cohort of people prescribed opioid agonist treatment: A predictive modelling study. Jones N.R., Hickman M., Bharat C., Nielsen S., Larney S., Ghouse N.F., et al., p. 2044-2054.
- Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experience. Lowry N., McKechnie A., Day E., Gilvarry E., Cowden F., Evans R., et al., p. 2055-2066.
- Effects of acute psychosocial stress on cue-reactivity, attentional bias and implicit associations in women with problematic social network use: An experimental study. Kessling A., Müller A., Wolf O.T., Merz C.J., Brand M., Wegmann E., p. 2067-2079.
- Use of cessation products, e-cigarettes and cigarette cessation outcomes among adults with substance use problems: Results from 2013-2021 (Waves 1-6) of the Population Assessment of Tobacco and Health (PATH) Study. Erinoso O., Kasza K., Sheffer C.E., Hyland A., Pearson J., p. 2080-2093.
- A return on investment analysis for the 2017 increase in alcohol excise taxation in Lithuania. Rehm J., Rovira P., Hassan A.S., de Oliveira C., Lange S., Thompson M.J., et al., p. 2094-2104.
- Commentary on Rehm et al.: Utilizing return on investment analysis to advocate for tax increases. Subbaraman M.S., p. 2105-2106.
- Associations of plasma sex-related hormone and protein levels and alcohol dependence. Ho A.M., Geske J.R., Pazdernik V.K., Waller T.C., Batzler A., Winham S.J., et al., p. 2107-2117.
- Trajectories of hospital-presenting alcohol-related disorders between early and late adulthood: Exploring the role of mortality in a prospective study of a 1953 cohort. Bishop L., Brännström L., Almquist Y.B., p. 2118-2126.
- A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine. Deng C., Oviedo E., Fishman M., Burgess-Hull A., p. 2127-2133.
- Estimating recent trends in alcohol sales in the United Kingdom from alcohol duty revenue. Angus C., Schöley J., p. 2134-2140.
- Understanding medical cannabis use internationally: Why definitions and context matter. Graham M., Pacula R.L., Pessar S.C., Ge Y., Kritikos A.F., Hall W., et al., p. 2141-2146.
- Isaac Campos. Home grown: Marijuana and the origins of Mexico's war on drugs. Hall W., Yeates S., p. 2147-2150.
- Advancing cognitive behaviour therapy for gaming disorder: A call for collaborative action. Radunz M., Stevens M.W.R., Behm S., Demetrovics Z., Delfabbro P., King D.L., p. 2152-2153.
- The emerging landscape of etomidate e-cigarettes use. Ng C.Z., Hamood Said Al-Aamari H., Low L.T.K., Zhang M.W., p. 2154-2155.
- Cannabis use patterns and comparison trends in Canada. Fischer B., Jutras-Aswad D., Le Foll B., Myran D., p. 2156-2157.